Stryker Co. (NYSE:SYK) Stock Holdings Increased by Birch Hill Investment Advisors LLC

Birch Hill Investment Advisors LLC boosted its stake in Stryker Co. (NYSE:SYK) by 29.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 795 shares of the medical technology company’s stock after buying an additional 181 shares during the period. Birch Hill Investment Advisors LLC’s holdings in Stryker were worth $286,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of SYK. Ritholtz Wealth Management lifted its position in shares of Stryker by 6.3% during the 3rd quarter. Ritholtz Wealth Management now owns 5,140 shares of the medical technology company’s stock valued at $1,857,000 after acquiring an additional 306 shares during the last quarter. InTrack Investment Management Inc grew its stake in Stryker by 8.1% during the 3rd quarter. InTrack Investment Management Inc now owns 3,612 shares of the medical technology company’s stock valued at $1,305,000 after acquiring an additional 271 shares in the last quarter. Mechanics Bank Trust Department increased its stake in Stryker by 5.0% in the 3rd quarter. Mechanics Bank Trust Department now owns 7,563 shares of the medical technology company’s stock valued at $2,732,000 after buying an additional 359 shares during the period. Annex Advisory Services LLC raised its holdings in shares of Stryker by 6.0% during the third quarter. Annex Advisory Services LLC now owns 8,314 shares of the medical technology company’s stock worth $3,004,000 after acquiring an additional 471 shares in the last quarter. Finally, Retirement Planning Group LLC purchased a new stake in shares of Stryker during the 3rd quarter worth about $249,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 5.90% of the stock is currently owned by corporate insiders.

Stryker Stock Performance

Shares of NYSE:SYK opened at $391.42 on Monday. The stock has a market capitalization of $149.22 billion, a price-to-earnings ratio of 50.44, a price-to-earnings-growth ratio of 2.98 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The business’s fifty day moving average price is $377.23 and its two-hundred day moving average price is $364.97. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the company earned $3.46 earnings per share. As a group, analysts predict that Stryker Co. will post 13.49 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is presently 43.30%.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of recent research reports. Royal Bank of Canada raised their price target on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Evercore ISI lifted their price target on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. raised their target price on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $370.00 to $445.00 in a research report on Monday, December 2nd. Finally, StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average price target of $419.37.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.